Pfizer Repurposing Chatter Is Already in the Tape: Fade the Narrative, Not the Company
The Opportunity
Upstream direction is FADE, and that is the correct posture: the signal is explicitly routed to propagation monitor with a decaying edge profile. In plain English, whatever the repurposing story is, it is already spreading across Tier-1 channels, which means the informational advantage is largely gone. The right "call" here is not a new LONG or SHORT; it is to avoid treating this as fresh edge in a choppy tape.
The Timing
In Bearish 72 conditions with crosswind risk at 78, late-cycle narratives are where you get whipsawed: you are trading second-order reactions, not the original information. This stays AVOID until something changes the state: either (a) a new primary artefact resets the story with genuinely new data, or (b) the signal is reframed into a specific, testable milestone with an instrument mapping and a dated catalyst. Without that, the best use of this item is as a reminder that crowded narratives have poor risk/reward.
The Evidence
This payload segment does not include hydrated evidence URLs for ED-009, and 7A labels it as edge decay with low information edge (score 0.24) and spreading lifecycle. That absence is itself consistent with a late-stage, already-distributed theme rather than a single, linkable new artefact inside this run. Without primary artefacts in the hydrated bundle, we do not treat it as executable intelligence.